As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price target Compass’ most advanced product candidate tovecimig is currently in a Phase 2/3 trial “COMPANION-002” in patients with advanced biliary tract cancer with top-line results guided for end-of-Q1, notes the analyst, who believes the risk/reward heading into top-line results is “positive” based on reported monotherapy and chemotherapy combination data showing encouraging clinical activity in solid tumors and potential differentiation from prior generations of similar drugs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics initiated with a Buy at Guggenheim
- Compass Therapeutics initiated with an Overweight at Piper Sandler
- Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline
- Two new option listings on February 11th
- Optimistic Buy Rating for Compass Therapeutics Due to Promising CTX-009 Trial Results and Market Potential
Questions or Comments about the article? Write to editor@tipranks.com